Grifols Biotest AG Investment 2021 Acquisition

Presentation outlining Grifols' acquisition of Biotest AG, a bioscience company specializing in plasma-derived therapies and transfusion medicine diagnostics. The investment highlights Biotest's four core divisions: Bioscience (78% of revenues), Diagnostic (15%), Hospital (3%), and Bio Supplies (4%), positioning Grifols as a global leader in essential plasma-based healthcare solutions.